Your browser doesn't support javascript.
A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease.
Foster, Stephanie L; Woolsey, Courtney; Borisevich, Viktoriya; Agans, Krystle N; Prasad, Abhishek N; Deer, Daniel J; Geisbert, Joan B; Dobias, Natalie S; Fenton, Karla A; Cross, Robert W; Geisbert, Thomas W.
  • Foster SL; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610.
  • Woolsey C; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555-0610.
  • Borisevich V; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610.
  • Agans KN; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555-0610.
  • Prasad AN; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610.
  • Deer DJ; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555-0610.
  • Geisbert JB; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610.
  • Dobias NS; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555-0610.
  • Fenton KA; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610.
  • Cross RW; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555-0610.
  • Geisbert TW; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610.
Proc Natl Acad Sci U S A ; 119(12): e2200065119, 2022 03 22.
Article in English | MEDLINE | ID: covidwho-1740535
ABSTRACT
SignificanceConcern has increased about the pandemic potential of Nipah virus (NiV). Similar to SARS-CoV-2, NiV is an RNA virus that is transmitted by respiratory droplets. There are currently no NiV vaccines licensed for human use. While several preventive vaccines have shown promise in protecting animals against lethal NiV disease, most studies have assessed protection 1 mo after vaccination. However, in order to contain and control outbreaks, vaccines that can rapidly confer protection in days rather than months are needed. Here, we show that a recombinant vesicular stomatitis virus vector expressing the NiV glycoprotein can completely protect monkeys vaccinated 7 d prior to NiV exposure and 67% of animals vaccinated 3 d before NiV challenge.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Vaccines, Synthetic / Primate Diseases / Nipah Virus / Henipavirus Infections Type of study: Diagnostic study / Prognostic study Topics: Vaccines Limits: Animals Language: English Journal: Proc Natl Acad Sci U S A Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Vaccines, Synthetic / Primate Diseases / Nipah Virus / Henipavirus Infections Type of study: Diagnostic study / Prognostic study Topics: Vaccines Limits: Animals Language: English Journal: Proc Natl Acad Sci U S A Year: 2022 Document Type: Article